Insmed (NASDAQ:INSM) will release its earnings data before the market opens on Friday, February 22nd. Analysts expect Insmed to post earnings of ($1.10) per share for the quarter.
Shares of NASDAQ:INSM opened at $27.07 on Tuesday. Insmed has a 52-week low of $11.31 and a 52-week high of $31.58. The company has a market capitalization of $2.09 billion, a P/E ratio of -9.37 and a beta of 2.91. The company has a current ratio of 10.06, a quick ratio of 10.06 and a debt-to-equity ratio of 1.07.
In other Insmed news, Director Alfred Altomari sold 5,500 shares of the stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $22.50, for a total transaction of $123,750.00. Following the sale, the director now owns 42,442 shares of the company’s stock, valued at approximately $954,945. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.88% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4163374/insmed-insm-to-release-quarterly-earnings-on-friday.html.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Featured Article: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.